Pfizer’s Booster protects against omicrons

Researchers have In a population study, evidence found that the effect of the corona vaccines from Biontech and Astra-Zeneca against the Omikron variant is weaker than against the Delta variant. A booster vaccination increases the protection against symptomatic infection, report the researchers led by Nick Andrews from the UK Health Security Agency (UKHSA) in a study that has not yet been examined by colleagues. “This important UK study on Omikron shows for the first time more clearly how contagious the variant is,” wrote Federal Health Minister Karl Lauterbach on Twitter on Saturday. “Early booster vaccination seems sensible, probably necessary.” The researchers emphasize that the results should be interpreted with caution, partly due to the still low number of infections with the Omikron variant.

The scientists had detected the omicron variant in a total of 581 symptomatic infections. In the same period, more than 56,000 infections with the Delta variant were confirmed. Evaluation of the data showed that protection against symptomatic infection with Omikron was 15 weeks after the second dose Biontech on 34 percent sinks. People with two cans of the Astra-Zeneca– had been vaccinated no longer protection against symptomatic infection. Two weeks after one Booster vaccination the protective effect increased with both preparations over 70 percent.

In the Delta variant The vaccination protection decreased from the 25th week after the second dose to just under 42 percent (Astrazeneca), or to 63.5 percent (Biontech). A booster shot increased protection to over 90 percent. Two doses of the examined vaccines were insufficient to effectively protect against infection and mild illness after infection with the omicron variant, the researchers conclude. The data did not permit any statements about protection against serious illness. It is also unclear how long the improved protection will last after the booster vaccination.

.
source site-12